Drugs / HS-20093
HS-20093
Trials 29 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07268053 | Feb 2026 → Jul 2027 expected | glioblastoma, metastatic malignant neoplasm in the brain | Nader Sanai | Recruiting | No outcome recorded |
| Phase 113 trials | ||||||
| Phase 1 | NCT07462923 | Jan → Dec 2026 expected | adenocarcinoma | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
| Phase 1 | NCT07277270 | Dec 2025 → Jul 2026 overdue | neoplasm | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 1 | NCT07186452 | Sep 2025 → Jul 2026 overdue | cancer | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
| Phase 1 | NCT07115446 | Aug 2025 → Dec 2027 expected | prostate cancer | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
| Phase 1 | NCT07063407 | Jul 2025 → Apr 2026 overdue | small cell lung carcinoma | Shanghai Hansoh Biomedical Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06963502 | May 2025 → Dec 2028 expected | colorectal cancer, non-small cell lung carcinoma | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06769425 | May 2025 → May 2026 overdue | female breast carcinoma, gastric cancer, ovarian cancer, prostate cancer +1 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06699576 | Dec 2024 → Dec 2026 expected | osteosarcoma, soft tissue sarcoma | Hansoh BioMedical R&D Company | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06621563 | Dec 2024 → Mar 2026 overdue | colorectal cancer, non-small cell lung carcinoma | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
| Phase 1 | NCT06825624 | Oct 2024 → Oct 2026 expected | colorectal cancer | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
| Phase 1 | NCT06332170 | Apr 2024 → May 2026 overdue | neoplastic disease or syndrome | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
| Phase 1 | NCT05277051 | Mar 2022 → Aug 2027 expected | neoplasm | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05276609 | Nov 2021 → Dec 2023 | neoplasm | Shanghai Hansoh Biomedical Co., Ltd | Unknown | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07602777 | Jun 2026 → Nov 2027 expected | sarcoma | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06885034 | Jun 2025 → Jan 2028 expected | digestive system neoplasm | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT07408063 | Apr 2026 → Jun 2030 expected | head and neck squamous cell carcinoma | University Health Network, Toronto | Recruiting | No outcome recorded |
| Phase 2 | NCT07230106 | Dec 2025 → Dec 2028 expected | prostate cancer | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06052423 | Nov 2024 → Jun 2025 | small cell lung carcinoma | Hansoh BioMedical R&D Company | Withdrawn | No outcome recorded |
| Phase 2 | NCT06112704 | Feb 2024 → Jul 2026 overdue | neoplasm | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
| Phase 2 | NCT06001255 | Jan → Dec 2024 overdue | castration-resistant prostate carcinoma | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
| Phase 2 | NCT06007729 | Dec 2023 → Dec 2025 overdue | head and neck squamous cell carcinoma | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
| Phase 2 | NCT05830123 | Jun 2023 → Dec 2025 overdue | osteosarcoma | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
| Phase 36 trials | ||||||
| Phase 3 | NCT07621601 | Jul 2026 → Dec 2030 expected | esophageal squamous cell carcinoma | Hansoh BioMedical R&D Company | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07464327 | Mar 2026 → Dec 2028 expected | non-small cell lung carcinoma | Hansoh BioMedical R&D Company | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07099898 | Aug 2025 → Nov 2027 expected | lung neoplasm | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 3 | NCT06935409 | Apr 2025 → Aug 2026 overdue | osteosarcoma | Hansoh BioMedical R&D Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06526624 | Sep 2024 → Nov 2027 expected | small cell lung carcinoma | Hansoh BioMedical R&D Company | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06498479 | Jul 2024 → Sep 2026 expected | small cell lung carcinoma | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 29 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-20093 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06001255 ↗ |
| Known as | GSK5764227 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05277051 ↗ |
| Known as | Ris-Rez | “In this study researchers are testing Risvutatug rezetecan also known as (Ris-Rez) a new medicine that targets specific proteins (B7-H3) on cancer cells” NCT07099898 ↗1“The main goal of this study is to test a new medicine, Risvutatug Rezetecan also called Ris-Rez.” NCT07602777 ↗ |
| Known as | Risvutatug Rezetecan | “In this study researchers are testing Risvutatug rezetecan also known as (Ris-Rez) a new medicine that targets specific proteins (B7-H3) on cancer cells” NCT07099898 ↗2“The main goal of this study is to test a new medicine, Risvutatug Rezetecan also called Ris-Rez.” NCT07602777 ↗ |
| Action | Deplete | “delivers a toxin directly to cancer cells to destroy them while sparing healthy cells” NCT07277270 ↗ |
| Modality | Other / unclassified | “fully humanized IgG1 antibody-drug conjugate (ADC)” NCT05830123 ↗ |
| Route | Intravenous | “Intravenous (IV) administration of HS-20093 Q3W” NCT05276609 ↗ |